China
Africa
Explore chapters and articles related to this topic
Drug Therapy for Obesity
Published in Ruth Chambers, Paula Stather, Tackling Obesity and Overweight Matters in Health and Social Care, 2022
Prescription drugs such as serotonin-receptor agonists for treating depression (such as fluoxetine) are sometimes prescribed for bulimia or binge eating disorder. But there is limited and conflicting evidence that fluoxetine has any beneficial effect on obesity. It is neither licensed nor recommended for this purpose.4
Weight and health
Published in Sally Robinson, Priorities for Health Promotion and Public Health, 2021
Binge eating disorder means that people are unable to prevent themselves from eating large amounts of food, often in a short time span. Eating feels out of control. Compulsive overeating is a milder form of binge eating. It could include recurrent trips to the cupboard looking for something to eat, constant nibbling or a lack of control around certain foods such as chocolate. Both include eating faster than normal, beyond feeling full; eating when not hungry; eating alone or in secret; feeling guilty or upset after eating; feeling ‘taken over’ and then trying to compensate for the overeating by dieting. Someone with these conditions is likely to be overweight.
Eating Disorders
Published in Cathy Laver-Bradbury, Margaret J.J. Thompson, Christopher Gale, Christine M. Hooper, Child and Adolescent Mental Health, 2021
For children and young people with binge-eating disorder, the principles of treatment are the same as for adults with binge-eating disorder, but tailored to the young person’s developmental needs. Binge-eating-disorder-focussed guided self-help programmes include cognitive behavioural self-help materials and supportive sessions, e.g. 4 to 9 sessions lasting 20 minutes each over 16 weeks, running weekly at first.
Eating disorders during the COVID-19 pandemic and quarantine: an overview of risks and recommendations for treatment and early intervention
Published in Eating Disorders, 2022
Marita Cooper, Erin E. Reilly, Jaclyn A. Siegel, Kathryn Coniglio, Shiri Sadeh-Sharvit, Emily M. Pisetsky, Lisa M. Anderson
Most individuals with EDs do not seek professional care for their symptoms due to barriers such as access, cost, stigma, and scarcity of expert training, thereby underscoring the importance of specialized self-help interventions for EDs (Sadeh-Sharvit, 2019). Additionally, vulnerable populations report the need for greater support during the COVID-19 pandemic (Yang et al., 2020). While different factors may contribute to reasons underlying a lack of access to care, robust data support the usefulness of self-help for individuals with EDs (Melioli et al., 2016), including fully digital and book-based programs (Hildebrandt et al., 2017). Self-help can be unguided, completed independently, or guided, i.e., enhanced by a facilitator (a therapist or a pre-licensed provider) who helps program participants to implement and adapt the curriculum to their lives (Wilson & Zandberg, 2012). Self-help for EDs has been successfully investigated for individuals with anorexia nervosa, bulimia nervosa, and binge-eating disorder using interventions informed by family-based treatment, cognitive behavioral therapy, and dialectical behavior therapy, respectively (Fairburn, 2013; Kenny et al., 2019; Lock et al., 2017). The majority of the specific interventions informing self-help approaches (such as self-monitoring, psychoeducation, urge surfing, and problem-solving) are feasible to implement while adhering to physical distancing requirements.
Addiction to binge eating among women in psychologically abusive relationships: The moderating role of defense mechanisms
Published in Health Care for Women International, 2021
Orly Yona-Drori, Shirley Ben-Shlomo
Binge eating disorder (BED) is a behavioral disorder marked by a loss of control over food consumption (DSM-5 American Psychiatric Association, 2013) as well as continued excessive consumption despite the negative consequences and emotions engendered (Gearhardt et al., 2012). According to the World Health Organization (WHO), the disorder constitutes a public health problem at least on the scale of bulimia nervosa (BN), although country-specific lifetime prevalence estimates are consistently higher for BED (1.4%; .8–1.9%) than BN (.8%; .4–1.0%) (Kessler et al., 2013). A high percentage of binge eaters are in a state of addiction (Gearhardt et al., 2012), this being the basis for the disorder. The ability to recognize the addiction component of this disorder, as well as the emotional mechanisms underlying it requires an interdisciplinary perspective of physicians, clinical dietitians and clinical psychotherapists.
Investigational drugs for the treatment of binge eating disorder (BED): an update
Published in Expert Opinion on Investigational Drugs, 2019
Jose C. Appolinario, Antonio E. Nardi, Susan L. McElroy
We searched PubMed from inception to August 2019 to identify pharmacological interventions for the management of binge eating disorder in adults using the following terms: ‘binge eating’, ‘pharmacological treatment’, ‘drug treatment’, and ‘pharmacotherapy’. In our search, we included clinical studies (randomized controlled trials, non-randomized studies and case series/reports) in human and animals. Clinical trials were searched also at ClinicalTrials.gov. Search results were assessed for their overall relevance to this review. There were no exclusion criteria. We complemented our search with additional references cited in the bibliography of selected studies. Our search generated 599 references (PubMed = 432, clincaltrials.gov = 162, other sources = 5). Ninety-seven articles were assessed for eligibility and 48 were included in this review (43 of these were clinical studies, and 5 were systematic or narrative reviews). The studies selected are presented below under the following categories: approved pharmacological treatment for BED, investigational pharmacological treatment for BED, other agents studied in BED and additional agents.